Hospital

Lack of immediate results, cultural barriers, and high costs lead many to gamble with their cardiovascular health, study results show.

The calculation instrument displayed good discrimination, with a C-index of 0.72, as well as good calibration, investigators say.

Data suggest that omicron-specific CD8-positive T cell responses were more than 80% cross-reactive with the CD8-positive T cell response to the original strain of the virus.

Larotrectinib was the first drug to receive accelerated FDA approval for patients of all ages based on a common molecular marker, independent of tissue origin for targeted therapy.

Applying these findings in practice could improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data predicting patients’ responses.

Fecal microbiota transplantation produces cure rates of 82%-88% in patients with recurrent clostridium difficile infections.

Selinexor demonstrated a 37% increase in probability that patients treated with the drug will be in remission at 12 months.

The use of a unique trimer to produce tier-2 neutralizing antibodies may help fight HIV.

Sutimlimab-jome is the only approved treatment for individuals with CAD and works by inhibiting the destruction of red blood cells.

Following the first 3 days after a COVID-19 diagnosis, the risk of stroke quickly decreased.

Monoclonal antibodies are highly effective at treating the virus, but they have often gone to the healthiest patients, instead of those over aged 65 years.

Culturally tailored patient navigation can improve underserved individuals’ health literacy, trust in the health care system, and use of cancer screening tools, study results show.

The results of a pilot program investigating the efficacy of remote patient monitoring for patients with cancer showed that it helped to keep high-risk individuals out of the hospital.

Communication, flexibility, and virtual solutions will remain key as the COVID-19 pandemic continues.

Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.

Millions of people are still getting COVID-19, so the need for additional tools to fight the virus remains strong.

But 3 main challenges stand in the way of their adoption: patent litigation, patient and physician concerns, and rebates and reimbursements.

Investigators also found that intravenous immunoglobulins tend to be associated with increased frequency, though not significant, of serious adverse events.

Pfizer and BioNTech are seeking an Emergency Use Authorization for their COVID-19 vaccine to include children 6 months through 4 years of age.

Although the researchers were able to find an association between a heart attack and faster cognitive decline, the findings did not establish that a heart attack directly causes cognitive decline.

Greenstick fractures occur most commonly in children because their bones are softer and more flexible than the bones of adults.

Investigators say more research is needed to better define the etiological sex differences in young adults and the contributions of nontraditional risk factors.

New study results show that the drugs, which block estrogen production, are more effective for premenopausal and postmenopausal women.

The research team looked at tumor samples, CT scans, and immune markers from the patients, finding that those who had taken part in the exercise program showed a better response to the chemotherapy.

Stuart Staggs, senior director of strategic programs at McKesson, discussed the encouraging metrics associated with use of the Oncology Care Model (OCM) sponsored by the Centers for Medicare and Medicaid Services.

Lower use of antimicrobials for clostridium difficile infection associated with a shorter length of stay in hospitals.

Preliminary research results show that immigrants from Africa have lower rates of CVD and stroke.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.